David Stadermann
Product Development and CMC expert
Mr. Stadermann is a trained Chemical Engineer and orally inhaled and nasal drug product-development specialist with over 15 years of experience in the development and manufacturing of pMDIs and DPIs. He has strong technical expertise in the development, submission, and patent litigations of inhalation drug substances and drug products. He has a proven track record in both generic and innovative development at a number of prestigious pharmaceutical companies, including Teva, Solvay, and Merck.
Mr. Stadermann has authored CMC sections for various clinical and commercial inhalation products and has directly engaged with global regulatory authorities (EMEA, US, JP, LATAM, and RoW). Among his key achievements are the successful development and approval of budesonide/formoterol and fluticasone/salmeterol products.